



KS124	Anti Human CD9 (MRP-1) Monoclonal Antibody (Clone No. 6D11)		
Primary Source	HGNC:1709	Application	
Туре	Monoclonal	WB	1.0-5.0 μg/mL
Immunogen	Human Cancer Cell Line	IHC	10.0 μg/mL
Raised in	Mouse	ICC	Not tested
Myeloma	P3U1	ELISA	Not tested
Clone number	6D11	FCM	1.0-5.0 μg/mL
Isotype	lgG2a, к	Neutralization	Not tested
Source	Serum Free Medium	IP	5.0-10.0 μg/mL
Purification notes	ProteinG		
Cross Reactivity	Not yet tested in other species.		
Concentration	0.25 mg/mL		
Contents (Volume)	50 μg (200 μL/vial)		
Label	Unlabeled		
Buffer	PBS [containing 2 % Block Ace as a stabilizer, 0.1 %Proclin as a bacteriostat]		
Storage	Store below –20 . Once thawed, store at 4 . Repeated freeze-thaw cycles should be avoided.		

Note

CD9 (also known as MRP-1: Motility-Related Protein 1) is a member of tetraspanin family. Tetraspanins comprise a family of over 30 membrane glycoproteins with four hydrophobic transmembrane domains. It has been reported that tetraspanins can regulate several biological and pathological process, including migration and metastasis, adhesion, cell proliferation, differentiation. The expression of many member of the family is changed in different types of carcinomas.

Clinical and pathologic findings indicate that down-regulation of CD9 correlates with tumor progression and metastasis, including melanoma, breast, lung, colon, prostate, pancreas and ovarian cancer. Moreover, transfection of CD9 inhibits cell motility and tumor metastasis.

This antibody is specific to human CD9 and will be useful for FCM, immunoprecipitation, immunohistochemistry, western blotting.

CD9 (MRP-1: Motility-Related Protein 1) は、テトラスパニンファミリーの一つです。テトラスパニンファミリーは 30 以上の膜糖タンパク質 で形成され、四つの疎水性膜貫通ドメインを持っています。テトラスパニンファミリーは、細胞の遊走、転移、接着、増殖、分化など に関与し、その多くで癌細胞における発現が変化することが知られています

これまでの研究で、CD9 の減少がメラノーマ、乳癌、肺癌、大腸癌、前立腺癌、膵臓癌、卵巣癌などの腫瘍形成促進及び転移に関 係していることが示されています。さらに、CD9 が細胞の運動性や腫瘍の転移を阻害することも明らかとなっています。 本抗体はヒトCD9 に特異的な抗体であり、FCM、免疫沈降、免疫組織染色、ウェスタンブロッティングに使用できます。

Reference

Funakoshi T. et al.: Expression of tetraspanins in human lung cancer cells: frequent downregulation of CD9 and its contribution to cel Oncogene.

2003 Feb 6;22(5):674-87. motility in small cell lung cancer. Down-regulation of CD9 in human ovarian carcinoma cell might contribute to peritoneal dissemination Cancer Res

Furuya M. et al.:

2005 Apr 1;65(7):2617-25. morphologic alteration and reduced expression of beta1 integrin subsets. Saito Y. et al.: Absence of CD9 enhances adhesion-dependent morphologic differentiation, survival, and matrix Cancer Res

metalloproteinase-2 production in small cell lung cancer cells. 2006 Oct 1;66(19):9557-65. De Bruyne E. et al.: Endothelial cell-driven regulation of CD9 or motility-related protein-1 expression in multiple myeloma cells within Leukemia

the murine 5T33MM model and myeloma patients. 2006 Oct;20(10):1870-9. Epub 2006 Aug 10.

WARNING AND PRECAUTION

- 1. Not for diagnostic use. The safety and efficacy of product in diagnostic or other clinical uses has not been
- 2. Harmful by inhalation, in contact with skin and if swallowed. Do not breathe dust. Avoid contact with skin and eyes.
- 3. If contact with skin and eyes, wash all affected areas with large volume of water. If inhaled remove to fresh air. In severe case obtain medical attention
- 4. Wash hand thoroughly after handling the product
- 5. Do not use this product if container is broken or some contaminants are detected.
- 6. When preserving the product, Close the container, ensure it does not fall aside or down.
- 7. Dispose of the container and expired reagents in accordance with federal, state and local government regulations
- 8. Do not use the container and accessories of the product for other purpose.

取り扱い上の注意

- 1. 本品は研究用試薬であり、医薬品その他の目的にはご使用になれません。
- 2. 取り扱い中は皮膚、粘膜、着衣に触れたり、目に入らないように適切な措置を行って下さい。
- 3. 試薬が誤って目や口に入った場合には、水で十分に洗い流すなどの応急処置を行い、必要があれ ば医師の手当を受けて下さい。
- 4. 取り扱い後には手洗いを十分に行って下さい。
- 5. 容器の破損、異物混入等異常が認められた物は使用しないで下さい。
- 6. 試薬を保管する場合は、蓋をし、転倒落下防止を確実にし、指定の貯蔵方法で保管して下さい。
- 使用後の容器は、廃棄物に関する規定に従って処理して下さい。
- 8. 容器、付属品等の他目的への転用は保証できません。